阿托伐他汀对冠心病患者炎症因子和血管内皮功能的疗效  

Therapeutic effect of atorvastatin on inflammatory factor levels and vascular endothelial function in patients with coronary heart disease

作　　者：王茜[1] 闵新文[1] 李东峰[1] 郎明健[1] 李兴朝[2] 

机构地区：[1]湖北医药学院附属东风医院心血管内科,湖北十堰442008 [2]湖北省十堰市太和医院儿童诊疗中心

出　　处：《心血管康复医学杂志》2017年第4期420-424,共5页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:探讨阿托伐他汀对冠心病患者炎症因子和血管内皮功能的疗效。方法:选择我院收治的冠心病患者112例,按照随机数字表法分为常规治疗组(56例)与阿托伐他组(56例)。疗程均为8周。比较两组患者治疗前后血清炎症因子水平、血管内皮功能变化,治疗后心绞痛和心电图疗效及用药期间不良反应情况。结果:与治疗前比较,两组治疗后血清白介素6(IL)-6、肿瘤坏死因子α(TNF)-α、C反应蛋白(CRP)、细胞间粘附因子1(ICAM)-1、内皮素(ET)-1水平均明显降低,一氧化氮(NO)水平、左室射血分数(LVEF)和心输出量(CO)明显增加(P均<0.01);且与常规治疗组比较,治疗后阿托伐他汀组血清IL-6[(157.42±30.13)pg/ml比(129.83±27.31)pg/ml]、TNF-α[(25.41±2.67)ng/L比(21.38±2.13)ng/L]、CRP[(19.87±2.78)mg/L比(17.13±2.04)mg/L]、ICAM-1[(81.23±19.83)pg/ml比(64.31±15.46)pg/ml]、ET-1[(1.45±0.34)pg/ml比(0.87±0.23)pg/ml]水平降低更显著,NO[(53.27±5.31)mmol/L比(58.72±5.46)mmol/L]水平、LVEF[(52.37±5.38)%比(63.19±5.79)%]和CO[(4.58±0.78)L/min比(5.13±0.82)L/min]增加更显著(P均<0.01);与常规治疗组比较,阿托伐他汀组心绞痛总有效率(73.22%比89.29%)、心电图总有效率(66.07%比83.93%)明显提高(P均<0.05);两组均未见严重用药不良反应。结论:阿托伐他汀可明显降低冠心病患者炎症因子水平,改善炎症状态,且可改善患者血管内皮功能。Objective： To explore therapeutic effect of atorvastatin on inflammatory factor levels and vascular endothelial function in patients with coronary heart disease （CHD）. Methods： A total of 112 CHD patients treated in our hospital were selected. According to random number table, they were randomly and equally divided into routine treatment group and atorvastatin group, and both groups were treated for eight weeks. Serum levels of inflammatory factors and vascular endothelial function before and after treatment, angina pectoris and ECG therapeutic effect af-ter treatment, and incidence of adverse reactions during medication were compared between two groups. Results： Compared with before treatment, after treatment, there were significant reductions in serum levels of interleukin （IL） -6, tumor necrosis factor （TNF） -5, C reactive protein （CRP）, intercellular adhesion molecule （ICAM） -1 and endothelin （ET） -1, and significant rise in nitric oxide （NO） level, left ventricular ejection fraction （LVEF） and cardiac output （CO） in both groups, P〈0.01 all; compared with routine treatment group after treatment, there were significant reductions in serum levels of IL-6 [ （157. 42 ± 30.13） pg/ml vs. （129.83±27.31） pg/ml], TNF-a E （25.41±2. 67） ng/L vs. （21.38±2. 13） ng/L], CRP [（19.87±2.78） mg/L vs. （17.13 ± 2.04） mg/L], ICAM-1[（81.23±19. 83） pg/ml vs. （64.31±15.46） pg/ml] and ET-1 [（1.45±0.34） pg/ml vs. （0.87±0.23） pg/ ml], and significant rise in NO level [ （53.27±5.31） mmol/L vs. （58.72±5.46） mmol/L], LVEF [（52.37±5.38）% vs. （63.19±5.79）%] and CO [（4.58±0. 78） L/min vs. （5.13±0.82） L/min] in atorvastatin group, P〈0.01 all. Compared with routine treatment group, there were significant rise in total effective rates of angina pectoris （73.22% vs. 89.29%） and ECG （66. 07% vs. 83.93%） in atorvastatin group, P〈0.05 both. There were no serious adverse drug reactions in two groups. Conclusion�

关 键 词：冠心病 炎症因子6 C反应蛋白质 内皮 血管 阿托伐他汀 

分 类 号：R541.4[医药卫生—心血管疾病]